Dr Rygiel Team

Tomasz Rygiel, Phd


We conduct research focused on the regulation of immune cell activation in the context of inflammatory diseases and cancer development. Understanding the mechanisms that control the immune response will allow them to be modulated for therapeutic purposes. The main areas of our interest are:

  • Regulation of the activity of myeloid cells by immunological inhibitory receptors (e.g., CD200R) and TLRs.
  • Regulation of the inflammatory process by CD200R
  • Use of macrophages as a cellular carrier of therapeutic compounds

Principal investigator

Dr Tomasz Rygiel, at 2002 finished Molecular Biology studies at University of Warsaw (Poland). Awarded with Scholarship of Socrates-Erasmus programme started in 2002 his Phd course at University of Amsterdam (The Netherlands). Five years lated defended his Phd thesis entitled "The role of Tiam1 in tumor cell biology" at Department of Cell Biology, Netherlands Cancer Institute/University of Amsterdam. Since 2007 started Post-doc at Department of Immunology, University Medical Center Utrecht, Utrecht (The Netherlands), where he focused on CD200R-mediated immune regulation in viral infections and anticancer response. Currently holds a position of Assistant professor, group leader at  , Department of Immunology, Medical University of Warsaw (Poland) where develops research at Role of CD200R-signaling in inflammation and cancer development.

Visiting Researcher:

  • 2002 - 2007 Netherlands Cancer Institute, Amsterdam, The Netherlands

  • 2007 – 2012 University Medical Center Utrecht, Utrecht, The Netherlands

Team members

Principal Investigator:  dr Tomasz Rygiel

Postdoctoral fellows: dr Zofia Pilch

PhD Students: mgr Agata Braniewska, mgr Zuzanna Sas

Msc Students: Karolina Korytkowska

Technicians: Marcin Skórzyński, Damian Strzemecki

Ongoing research projects
  • Innovative cell-based, targeted drug delivery method to the tumour. - Tomasz Rygiel, 2016-2020, (FNP).
  • Influence of CD200R singling pathway on angiogenesis in tumour microenvironment. Tomasz Rygiel, 2015-2019 (NCN).
Research papers 


The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies. Pilch Z, Tonecka K, Skorzynski M, Sas Z, Braniewska A, Kryczka T, Boon L, Golab J, Meyaard L, Rygiel TP. PLoS One. 2019 Jan 17;14(1):e0210796.


Changes in hypoxia level of CT26 tumors during various stages of development and comparing different methods of hypoxia determination. Kiraga Ł, Cheda Ł, Taciak B, Różańska K, Tonecka K, Szulc A, Kilian K, Górka E, Rogulski Z, Rygiel TP, Król M. PLoS One. 2018 Nov 9;13(11):e0206706. doi: 10.1371/journal.pone.0206706. eCollection 2018.

 Engineered ferritin for lanthanide binding. Calisti L, Trabuco MC, Boffi A, Testi C, Montemiglio LC, des Georges A, Benni I, Ilari A, Taciak B, Białasek M, Rygiel T, Król M, Baiocco P, Bonamore A. PLoS One. 2018 Aug 13;13(8):e0201859. 

 Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment. Pilch Z, Tonecka K, Braniewska A, Sas Z, Skorzynski M, Boon L, Golab J, Meyaard L, Rygiel TP. Cancer Immunol Res. 2018 Aug;6(8):930-940.

 Evaluation of phenotypic and functional stability of RAW 264.7 cell line through serial passages. Taciak B, Białasek M, Braniewska A, Sas Z, Sawicka P, Kiraga Ł, Rygiel T, Król M. PLoS One. 2018 Jun 11;13(6):e0198943

 Neutrophil-mediated Suppression of Influenza-induced Pathology Requires CD11b/CD18 (MAC-1). Tak T, Rygiel TP, Karnam G, Bastian OW, Boon L, Viveen M, Coenjaerts FE, Meyaard L, Koenderman L, Pillay J. Am J Respir Cell Mol Biol. 2018 Apr;58(4):492-499.


Interferon lambda 2 promotes mammary tumor metastasis via angiogenesis extension and stimulation of cancer cell migration. Pingwara R, Witt-Jurkowska K, Ulewicz K, Mucha J, Tonecka K, Pilch Z, Taciak B, Zabielska-Koczywas K, Mori M, Berardozzi S, Botta B, Rygiel TP, Krol M.


Low dose of GRP78-targeting subtilase cytotoxin improves the efficacy of photodynamic therapy in vivo. Gabrysiak M, Wachowska M, Barankiewicz J, Pilch Z, Ratajska A, Skrzypek E, Winiarska M, Domagala A, Rygiel TP, Jozkowicz A, Boon L, Golab J, Firczuk M. Oncol Rep. 2016 Jun;35(6):3151-8.

 Effects of cannabinoids and their receptors on viral infections. Tahamtan A, Tavakoli-Yaraki M, Rygiel TP, Mokhtari-Azad T, Salimi V. J Med Virol. 2016 Jan;88(1):1-12.

 Immune Cells in Cancer Therapy and Drug Delivery. Eyileten C, Majchrzak K, Pilch Z, Tonecka K, Mucha J, Taciak B, Ulewicz K, Witt K, Boffi A, Krol M, Rygiel TP. Mediators Inflamm. 2016;2016:5230219. 


The CD200-CD200 receptor inhibitory axis controls arteriogenesis and local T lymphocyte influx. van den Borne P, Rygiel TP, Hoogendoorn A, Westerlaken GH, Boon L, Quax PH, Pasterkamp G, Hoefer IE, Meyaard L. PLoS One. 2014 Jun 4;9(6):e98820

 5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. Wachowska M, Gabrysiak M, Muchowicz A, Bednarek W, Barankiewicz J, Rygiel T, Boon L, Mroz P, Hamblin MR, Golab J. Eur J Cancer. 2014 May;50(7):1370-81. 

 Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. Winiarska M, Bojarczuk K, Pyrzynska B, Bil J, Siernicka M, Dwojak M, Bobrowicz M, Miazek N, Zapala P, Zagozdzon A, Krol M, Syta A, Podszywalow-Bartnicka P, Pilch Z, Dabrowska-Iwanicka A, Juszczynski P, Efremov DG, Slabicki M, Zenz T, Le Roy A, Olive D, Rygiel TP, Leusen JH, Golab J. MAbs. 2014;6(5):1300-13.